Xtandi US20230382870, Enzalutamide US10053433, FC 4.129 BDBM50425732 US11648234, Compound Enzalutamide US11230523, Compound Enzalutamide US10806720, Compound Enzalutamide ENZALUTAMIDE
- Barrett, RRG; Nash, C; Diennet, M; Cotnoir-White, D; Doyle, C; Mader, S; Thomson, AA; Gleason, JL Dual-function antiandrogen/HDACi hybrids based on enzalutamide and entinostat. Bioorg Med Chem Lett 55: (2022)
- Pertusati, F; Ferla, S; Bassetto, M; Brancale, A; Khandil, S; Westwell, AD; McGuigan, C A new series of bicalutamide, enzalutamide and enobosarm derivatives carrying pentafluorosulfanyl (SF Eur J Med Chem 180: 1-14 (2019)
- Bassetto, M; Ferla, S; Pertusati, F; Kandil, S; Westwell, AD; Brancale, A; McGuigan, C Design and synthesis of novel bicalutamide and enzalutamide derivatives as antiproliferative agents for the treatment of prostate cancer. Eur J Med Chem 118: 230-43 (2016)
- He, Y; Hwang, DJ; Ponnusamy, S; Thiyagarajan, T; Mohler, ML; Narayanan, R; Miller, DD Pyrazol-1-yl-propanamides as SARD and Pan-Antagonists for the Treatment of Enzalutamide-Resistant Prostate Cancer. J Med Chem 63: 12642-12665 (2020)
- He, Y; Hwang, DJ; Ponnusamy, S; Thiyagarajan, T; Mohler, ML; Narayanan, R; Miller, DD Exploration and Biological Evaluation of Basic Heteromonocyclic Propanamide Derivatives as SARDs for the Treatment of Enzalutamide-Resistant Prostate Cancer. J Med Chem 64: 11045-11062 (2021)
- Hwang, DJ; He, Y; Ponnusamy, S; Mohler, ML; Thiyagarajan, T; McEwan, IJ; Narayanan, R; Miller, DD New Generation of Selective Androgen Receptor Degraders: Our Initial Design, Synthesis, and Biological Evaluation of New Compounds with Enzalutamide-Resistant Prostate Cancer Activity. J Med Chem 62: 491-511 (2019)